312 results
8-K
EX-99.1
TOVX
Theriva Biologics Inc
23 May 24
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
8:20am
serious conditions and fill an unmet medical need. Benefits of FTD to programs include early and frequent interactions with the FDA during the clinical … to derive benefits from FTD; the Company’s and VCN’s ability to reach clinical milestones when anticipated, including the ability to continue to enroll
8-K
EX-99.1
TOVX
Theriva Biologics Inc
7 May 24
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
7:05am
to complete clinical trials on time and achieve the desired results and benefits,; the ability to obtain regulatory approval for commercialization …
Deposits and other assets
Total Assets
Liabilities and Stockholders‘ Equity
Current Liabilities:
Accounts payable
Accrued expenses
Accrued employee benefits
8-K
EX-99.1
TOVX
Theriva Biologics Inc
23 Apr 24
Regulation FD Disclosure
7:00am
results and benefits,; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory
8-K
EX-99.1
e1ukt
22 Apr 24
Regulation FD Disclosure
4:36pm
8-K
EX-99.1
muepnl
16 Apr 24
Regulation FD Disclosure
8:00am
8-K
EX-99.1
042czsa 4fb
25 Mar 24
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
7:40am
8-K
EX-99.1
iqdkdv0 8ppsa9w
7 Feb 24
Regulation FD Disclosure
8:10am
8-K
EX-99.1
exij2 hj4
8 Jan 24
Regulation FD Disclosure
8:10am
8-K
EX-99.1
xaaatmzauelbqurax0
13 Nov 23
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
8:10am
8-K
EX-99.1
hp2tuwjbguvwjik0
23 Oct 23
Regulation FD Disclosure
7:10am
8-K
EX-99.1
p7ins1kdabe2jyhsn
17 Oct 23
Regulation FD Disclosure
6:05am
DEFR14A
rbfxty8xx7yd6a
16 Aug 23
Revised proxy
5:24pm